Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819255 · ClinicalTrials.gov registry record
TRAQinform Assessment of Immunotherapy Response
A clinical trial, sponsored by AIQ Solutions.
- Completed
- Registry status
- 26
- Enrollment target
NCT05819255: Completed study, sponsored by AIQ Solutions.
NCT05819255 is a clinical trial that has completed, run by AIQ Solutions. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05819255 has completed, sponsored by AIQ Solutions.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Primary Outcome
Treatment response will be analyzed using TRAQinform Immuno Technology which is a software technology that identifies, matches, and quantifies metastatic cancer regions of interest. The clinical study will evaluate investigator questionaries to help understand the clinical impact of the addition of the TRAQinform Immuno analysis into the clinical work flow.
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2025-04-30 |
What the finished NCT05819255 record still lists
NCT05819255 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT05819255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05819255 about?
NCT05819255 is a clinical study titled "TRAQinform Assessment of Immunotherapy Response". The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive ...
What is the current status of trial NCT05819255?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2023-06-23. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05819255?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT05819255?
This trial is sponsored by AIQ Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI